查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1834182

2025-2032 年全球人工 T 細胞市場預測（按治療類型、細胞來源、階段、應用和最終用戶分類）

Engineered T Cells Market by Therapy Type, Cell Source, Phase, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人工 T 細胞市場將成長至 224.2 億美元，複合年成長率為 26.44%。

主要市場統計數據
基準年2024年 34.3億美元
預計2025年 43.4億美元
預測年份：2032年 224.2億美元
複合年成長率（%） 26.44%

工程化T細胞的策略部署，專注於科學進步、有前景的治療方法、監管演變和相關人員的優先事項

在基因工程、細胞製造和轉化科學的推動下，工程化T細胞療法已從實驗室的好奇心發展成為現代免疫療法的變革性支柱。平台工程和概念驗證研究的最新進展使得標靶性更強、耐久性更高、安全管理更精細。這些改進加速了候選療法從臨床前模型到早期和晚期臨床評估的進展，拓寬了開發者的治療願景，使其從骨髓惡性腫瘤擴展到自體自體免疫感染疾病。

隨著科學研究能力的成熟，相關人員的優先事項也隨之轉變。研發人員必須協調複雜的生物學特性與可擴展的生產和監管預期，而支付方和醫療保健提供者也日益要求獲得持續效用和可預測安全性的證據。投資者和策略夥伴正在尋求明確TCR特異性和CAR模組化等差異化特徵，以及自體和異體培養之間的細胞來源決策。在此背景下，將實驗室創新與可操作的臨床路徑和供應鏈韌性相結合的組織策略將決定哪些專案能夠推進，哪些專案會停滯不前，這使得現在成為科研領導力和實際執行的關鍵時刻。

描繪重塑工程化 T 細胞開發、商業性途徑、突破性模式和協作生態系統的變革性轉變

工程化T細胞領域正在經歷幾場相互關聯的變革，這些變革正在重新定義開發模式和商業性途徑。基因編輯、載體設計和細胞製造的技術進步，正在賦能下一代CAR-T和TCR方法，使其特異性更高、脫靶效應更低，並具備模組化安全開關。同時，我們也看到了從單一場所的學術製造向整合但去中心化的製造網路的明顯轉變，該網路將集中式品管與局部能力相結合，以應對個性化和現成療法的運作現實。

臨床策略也在改變。開發商擴大在設計試驗時，將生物標記驅動的患者選擇和適應症終點納入考量，同時保持嚴格的監管要求。生物技術公司、大型製藥企業、合約研究公司和臨床網路之間的合作模式正在迅速擴展，這得益於將發現的靈活性與後期開發和商業化的優勢相結合的需求。同時，報銷討論正推進到研發早期階段，要求申辦方在製定臨床方案的同時，制定產生健康經濟證據的計畫。這些轉變正在改變投資標準、合作結構和競爭格局，有利於那些能夠同時推動生物創新和營運執行的組織。

評估 2025 年美國關稅將如何重塑人工 T 細胞供應鏈、採購、製造和國際合作

美國關稅將於2025年生效，這將為工程化T細胞計畫的全球供應和營運計算帶來新的變數。關稅波動可能會增加病毒載體、一次性耗材和專用試劑等關鍵投入的到岸成本。依賴跨境原料或契約製造的申辦者將需要重新評估供應商的多元化、緩衝庫存和合約條款，以維持專案時間表和臨床的連續性。

在實踐中，關稅環境凸顯了短期供應鏈可視性和緊急時應對計畫的重要性。區域組織可能更傾向於在受影響地區採購低成本組件與更靠近臨床站點的替代供應商提供的靈活性和彈性之間進行權衡。戰略應對措施包括重新談判供應商合約以分配關稅風險、在關稅穩定的地區確定合格的二級供應商，以及促進替代製造合作夥伴的技術轉移。監管提交和臨床時間表可能需要進行調整以反映這些營運變化，商業發布計劃應納入對成本結構和分銷變化的影響。整體而言，關稅變化凸顯了採購、製造、監管事務和商業團隊之間進行綜合規劃的必要性，以維持專案發展動能。

細分主導的洞察揭示了治療方法類型、細胞來源、開發階段、臨床應用和最終用戶將如何影響研發重點和策略

細分領域提供了一個視角，可以最有效地評估該領域的策略、臨床設計和投資決策。根據治療類型，計畫分為CAR-T和TCR-T兩種方法，每種方法都有不同的標靶框架、製造需求和轉化風險概況，這些因素會影響適應症重點和合作夥伴的利益。根據細胞來源，同種異體和自體療法之間的權衡會影響治療時間、擴充性、免疫抗原性風險和供應鏈複雜性，進而影響製造設計和商業化模式。根據階段，開發狀態從臨床前到I期、II期和III期，每個階段都有各自的證據要求、製造規模需求和監管互動，這些都會影響資源分配和批准/不批准時間。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 利用基因編輯降低移植物抗宿主風險的現成同種異體 CAR-T 療法的進展
  • 發展裝甲 CAR-T 細胞，分泌細胞激素以增強對固態腫瘤微環境的滲透
  • 透過 CRISPR 介導的多基因編輯提高 T 細胞持久性和安全性
  • 整合自動化、封閉式系統製造平台，擴大 CAR-T 生產規模並降低成本
  • 工程化T細胞與免疫查核點抑制劑的組合策略，以達到協同抗腫瘤反應
  • 針對雙抗原的雙特異性 CAR-T 構建體的出現，可防止治療抗藥性癌症中的腫瘤抗原逃脫
  • 不斷發展的基因改造T細胞療法監管途徑，重點在於統一的全球核准流程
  • 利用人工智慧演算法設計個人化新抗原靶向T細胞受體
  • 推出誘導性多功能幹細胞衍生的 CAR-T 產品，旨在標準化細胞治療供應鏈
  • 利用分子成像實現即時體內 CAR-T 細胞追蹤，以監測安全性和有效性
  • 市場進入舉措重點關注 CAR-T 療法的創新報銷模式和基於績效的契約

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 人工T細胞市場（依治療類型）

  • CAR T
  • TCR T

第9章：人工T細胞市場的細胞來源

  • 同種異體
  • 自體移植

第 10 章：人工 T 細胞市場（依階段）

  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前

第 11 章 人工 T 細胞市場：依應用

  • 自體免疫疾病
    • 狼瘡
    • 類風濕性關節炎
  • 感染疾病
  • 腫瘤學
    • 急性淋巴性白血病
    • 非何傑金氏淋巴瘤
    • 固態腫瘤
      • 神經膠母細胞瘤
      • 肺癌

第 12 章 人工 T 細胞市場（依最終用戶分類）

  • 醫院
  • 研究機構
  • 專科診所

第13章 人工T細胞市場：依地區

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章 人工 T 細胞市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國人工T細胞市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Novartis AG
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Legend Biotech Corporation
    • Allogene Therapeutics, Inc.
    • Adaptimmune Therapeutics plc
    • Poseida Therapeutics, Inc.
    • Celyad Oncology SA
    • Sangamo Therapeutics, Inc.
Product Code: MRR-4348D129FAA9

The Engineered T Cells Market is projected to grow by USD 22.42 billion at a CAGR of 26.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.43 billion
Estimated Year [2025] USD 4.34 billion
Forecast Year [2032] USD 22.42 billion
CAGR (%) 26.44%

Strategic introduction to engineered T cells emphasizing scientific advances, therapeutic promise, regulatory evolution, and stakeholder priorities

Engineered T cell therapeutics have evolved from a laboratory curiosity into a transformative pillar of modern immunotherapy, driven by advances in genetic engineering, cell manufacturing, and translational science. Recent years have seen progress not only in proof-of-concept studies but also in platform engineering, enabling more precise targeting, improved persistence, and refined safety controls. These improvements have accelerated the movement of candidate therapies from preclinical models into early and later-stage clinical evaluation, and they have broadened the therapeutic ambitions of developers beyond hematologic malignancies to autoimmune and infectious disease applications.

As scientific capabilities mature, stakeholder priorities are shifting in response. Developers must reconcile complex biology with scalable manufacturing and regulatory expectations, while payers and providers increasingly demand evidence of durable benefit and predictable safety. Investors and strategic partners are looking for clarity around differentiating features such as TCR specificity versus CAR modularity, and around cell source decisions between autologous and allogeneic approaches. Against this backdrop, organizational strategies that connect lab innovation to pragmatic clinical pathways and supply chain resilience will determine which programs advance and which stall, making this a pivotal moment for both scientific leadership and pragmatic execution.

Mapping transformative shifts reshaping engineered T cell development, commercial pathways, breakthrough modalities, and collaborative ecosystems

The engineered T cell field is undergoing several interconnected shifts that are redefining development paradigms and commercial pathways. Technological advances in gene editing, vector design, and cell manufacturing are enabling next-generation CAR and TCR approaches with improved specificity, reduced off-target activity, and modular safety switches. At the same time, there is a clear move from single-site academic manufacturing toward integrated yet distributed production networks that blend centralized quality control with local capacity, responding to the operational realities of personalized and off-the-shelf therapies.

Clinical strategy is also changing: developers are increasingly designing trials that embed biomarker-driven patient selection and adaptive endpoints to accelerate readouts while preserving regulatory rigor. Collaborative models between biotechs, large pharma, contract developers, and clinical networks are proliferating, driven by the need to combine discovery agility with late-stage development and commercialization muscle. Meanwhile, reimbursement conversations are moving earlier in development, prompting sponsors to design health economic evidence generation plans alongside clinical protocols. These shifts are reshaping investment criteria, partnership structures, and the competitive landscape, favoring organizations that can simultaneously innovate biologically and execute operationally.

Assessment of how United States 2025 tariffs could reshape engineered T cell supply chains, component sourcing, manufacturing and international collaboration

United States tariff measures implemented in 2025 introduce new variables into the global supply and operational calculus for engineered T cell programs. Changes in tariff exposure can increase the landed cost of critical inputs such as viral vectors, single-use consumables, and specialized reagents, which in turn pressures manufacturing economics and decisions about where to site production capacity. Sponsors that rely on cross-border flows for raw materials or contract manufacturing will need to reassess supplier diversification, buffer inventories, and contractual terms to preserve program timelines and clinical continuity.

In practice, the tariff environment amplifies the importance of near-term supply chain visibility and contingency planning. Organizations will increasingly evaluate the tradeoffs between sourcing lower-cost components from affected geographies versus the flexibility and resiliency provided by alternative suppliers closer to clinical sites. Strategic responses include renegotiating supplier agreements to allocate tariff risk, qualifying secondary suppliers in tariff-stable jurisdictions, and accelerating technology transfer to alternate manufacturing partners. Regulatory filings and clinical timelines may require adjustment to reflect these operational changes, and commercial launch planning must incorporate revised cost structures and distribution implications. Overall, tariff shifts highlight the need for integrated planning across procurement, manufacturing, regulatory affairs, and commercial teams to maintain program momentum.

Segment-driven insights revealing how therapy types, cell sources, development phases, clinical applications, and end users shape R&D focus and strategy

Segmentation provides the lens through which strategy, clinical design, and investment decisions are most meaningfully assessed in this domain. Based on Therapy Type, programs divide between CAR T and TCR T approaches, each with distinct targeting frameworks, manufacturing requirements, and translational risk profiles, which influence indication focus and partnering interest. Based on Cell Source, decisions between Allogeneic and Autologous approaches determine tradeoffs among time to treatment, scalability, immunogenicity risk, and supply chain complexity, and they inform manufacturing design and commercialization models. Based on Phase, development status ranges from Preclinical to Phase I, Phase II, and Phase III, with each stage presenting unique evidence requirements, manufacturing scale demands, and regulatory interactions that shape resource allocation and go/no-go timing.

Based on Application, therapeutic ambitions extend across Oncology, Infectious Diseases, and Autoimmune Diseases. The Oncology category includes hematologic indications such as Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma, as well as Solid Tumor programs targeting Glioblastoma and Lung Cancer, each presenting different tumor microenvironment challenges and delivery considerations. The Autoimmune Diseases segment further explores indications such as Lupus and Rheumatoid Arthritis, where long-term immune modulation and safety profiles require distinct trial designs. Based on End User, deployment contexts span Hospitals, Research Institutes, and Specialty Clinics, and these end users dictate logistics, in-hospital treatment pathways, and post-treatment monitoring frameworks. Together, these segmentation dimensions reveal where scientific opportunity aligns with operational capability and commercial access potential.

Regional dynamics across the Americas, EMEA, and Asia-Pacific that shape clinical trial activity, strategic partnerships, and patient access approaches

Regional dynamics materially influence development strategy, trial design, and access planning for engineered T cell programs. In the Americas, a dense ecosystem of clinical trial sites, academic centers, and specialized hospitals supports rapid patient accrual for hematologic and select solid tumor protocols, while regulatory pathways emphasize rigorous safety and efficacy evidence. Sponsors intending to launch in these markets must consider payer engagement earlier, as reimbursement expectations and hospital adoption patterns will shape commercial viability and pricing strategy. Cross-border collaborations with manufacturing and distribution partners are common, and logistical coordination across North and South American jurisdictions requires careful planning.

In EMEA, regulatory harmonization and clinical networks offer advantages for multicenter studies, but variations in national reimbursement and health technology assessment processes require tailored value demonstration strategies. Capacity constraints at transplantation and specialized cell therapy centers can influence site selection and operational timelines. In Asia-Pacific, there is a growing clinical and manufacturing footprint with strong public and private investment in advanced therapies, and adaptive regulatory initiatives in several markets can expedite local development and market entry. However, regional intellectual property considerations, local partnering norms, and differing healthcare delivery models require sponsors to adapt clinical, regulatory, and commercialization approaches to each submarket. Understanding these regional nuances is essential to align clinical development, manufacturing footprints, and market access plans.

Profiles of leading companies highlighting R&D platforms, manufacturing capabilities, partnership models, clinical pipelines, and commercialization priorities

Company-level dynamics are central to competitive positioning and partnership opportunities across the engineered T cell landscape. Leading developers are differentiating by technological platform-whether in CAR architecture, TCR discovery engines, gene editing methods, or safety switch implementations-and by the depth of their proprietary manufacturing know-how and scale capabilities. Strategic partnerships frequently pair early-stage innovators that hold unique targeting biology with larger organizations that provide late-stage development capacity, regulatory experience, and commercial infrastructure. Contract development and manufacturing organizations also play a pivotal role, offering modular solutions to reduce time to clinic and to support geographic expansion.

Investors and potential partners evaluate companies on a combination of scientific differentiation, clinical evidence progression across phases, supply chain robustness, and the clarity of commercialization pathways for target indications. Companies that articulate a compelling translational rationale, backed by reproducible manufacturing processes and an evidence generation plan addressing both clinical outcomes and health economic endpoints, are most likely to secure strategic collaborations and downstream commercial opportunities. Operational execution-ranging from vector supply to site training and long-term follow-up mechanisms-remains a critical determinant of whether scientific promise converts into sustainable therapeutic programs.

Practical recommendations for leaders to speed translation, optimize supply chains, forge strategic partnerships, and align regulatory/reimbursement approaches

Industry leaders should take immediate, prioritized actions to bridge scientific innovation with operational and commercial readiness. First, align clinical development plans with evidence needs of regulators and payers by integrating biomarker strategies, long-term follow-up protocols, and health economic endpoints into trial designs early. This alignment reduces the risk of later-stage surprises and strengthens value conversations at launch. Second, build supply chain resilience by qualifying secondary suppliers, exploring regional manufacturing hubs, and negotiating supplier contracts that include tariff and logistics contingencies. These measures reduce exposure to external shocks and support reliable clinical supply.

Third, pursue partnership models that complement internal capabilities: consider risk-sharing and co-development structures with partners that bring regulatory and commercialization scale, while preserving optionality for lead asset development. Fourth, invest in manufacturing transferability and quality systems that enable reproducible processes across sites, thereby reducing time to clinic and supporting broader geographic rollout. Finally, create cross-functional governance that connects R&D, manufacturing, regulatory affairs, and commercial teams to ensure coordinated decision-making on clinical prioritization, evidence generation, and market access strategies. These steps will enable organizations to convert program potential into measurable clinical and commercial outcomes.

Transparent research methodology outlining data sources, expert engagements, analytical frameworks, validation steps, and study limitations for decision-making

The research approach underpinning these insights combined a multi-method framework to ensure analytical rigor and practical relevance. Primary inputs included structured interviews with subject matter experts spanning clinical investigators, manufacturing leads, regulatory advisors, and commercial strategists to capture real-world operational constraints and strategic considerations. Secondary research reviewed peer-reviewed literature, publicly available regulatory guidance, company disclosures, and clinical trial registries to contextualize pipeline activity and therapeutic approaches. Analytical frameworks incorporated segmentation by therapy type, cell source, development phase, application, and end user to map where scientific innovation intersects with operational demand.

Validation steps included cross-checking expert statements against publicly disclosed trial and regulatory milestones, and synthesizing patterns across multiple data sources to mitigate single-source bias. Study limitations are acknowledged: proprietary commercial agreements and confidential development programs may not be fully reflected, and emerging technologies can evolve rapidly, which necessitates ongoing monitoring. Nevertheless, the combination of expert engagement, evidence triangulation, and structured analytical lenses provides a robust foundation for strategic planning and decision-making.

Concluding synthesis of strategic imperatives, scientific pathways, operations, and collaborative models shaping the future of engineered T cell therapeutics

The cumulative analysis highlights a clear imperative: converting engineered T cell promise into durable clinical and commercial impact requires simultaneous excellence in biology, manufacturing, and market execution. Scientific advances in CAR and TCR engineering offer pathways to expanded indications and improved therapeutic windows, but technical novelty alone is insufficient without scalable, quality-assured manufacturing and compelling evidence that addresses payer and provider expectations. Operational realities-from cell sourcing choices between autologous and allogeneic options to the phase-specific demands of clinical development-must be anticipated and integrated into program planning to avoid costly delays.

Collaborative models that pair nimble scientific organizations with partners that offer development scale and access capabilities will continue to dominate successful pathways to market. Regionally informed strategies are essential, as regulatory, clinical capacity, and reimbursement conditions vary across the Americas, EMEA, and Asia-Pacific. By aligning translational science with pragmatic operational planning and early payer engagement, stakeholders can increase the probability that engineered T cell innovations reach patients and sustain commercial viability. The path forward rewards integrated thinking and disciplined execution across the entire value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in off-the-shelf allogeneic CAR-T therapies using gene editing to reduce graft-versus-host risk
  • 5.2. Development of armored CAR-T cells secreting cytokines to enhance solid tumor microenvironment infiltration
  • 5.3. Incorporation of CRISPR-mediated multiplex gene editing to improve T cell persistence and safety profiles
  • 5.4. Integration of automated closed-system manufacturing platforms to scale up CAR-T production and reduce costs
  • 5.5. Combination strategies pairing engineered T cells with immune checkpoint inhibitors for synergistic antitumor response
  • 5.6. Emergence of bispecific CAR-T constructs targeting dual antigens to prevent tumor antigen escape in treatment-resistant cancers
  • 5.7. Regulatory pathways evolving for engineered T cell therapies with emphasis on harmonized global approval processes
  • 5.8. Adoption of artificial intelligence algorithms to design personalized neoantigen-targeted T cell receptors
  • 5.9. Launch of induced pluripotent stem cell-derived CAR-T products aiming to standardize cell therapy supply chains
  • 5.10. Implementation of real-time in vivo CAR-T cell tracking using molecular imaging for safety and efficacy monitoring
  • 5.11. Market access initiatives focusing on innovative reimbursement models and outcomes-based contracting for CAR-T therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Engineered T Cells Market, by Therapy Type

  • 8.1. CAR T
  • 8.2. TCR T

9. Engineered T Cells Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. Engineered T Cells Market, by Phase

  • 10.1. Phase I
  • 10.2. Phase Ii
  • 10.3. Phase Iii
  • 10.4. Preclinical

11. Engineered T Cells Market, by Application

  • 11.1. Autoimmune Diseases
    • 11.1.1. Lupus
    • 11.1.2. Rheumatoid Arthritis
  • 11.2. Infectious Diseases
  • 11.3. Oncology
    • 11.3.1. Acute Lymphoblastic Leukemia
    • 11.3.2. Non Hodgkin Lymphoma
    • 11.3.3. Solid Tumor
      • 11.3.3.1. Glioblastoma
      • 11.3.3.2. Lung Cancer

12. Engineered T Cells Market, by End User

  • 12.1. Hospital
  • 12.2. Research Institutes
  • 12.3. Specialty Clinics

13. Engineered T Cells Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Engineered T Cells Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Engineered T Cells Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Gilead Sciences, Inc.
    • 16.3.3. Bristol-Myers Squibb Company
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Legend Biotech Corporation
    • 16.3.6. Allogene Therapeutics, Inc.
    • 16.3.7. Adaptimmune Therapeutics plc
    • 16.3.8. Poseida Therapeutics, Inc.
    • 16.3.9. Celyad Oncology SA
    • 16.3.10. Sangamo Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENGINEERED T CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CAR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TCR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUPUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. GCC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 318. GCC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 319. GCC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 320. GCC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 321. GCC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. GCC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. GCC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 324. GCC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 325. GCC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. GCC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. GCC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 328. GCC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 329. GCC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. GCC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2